 Rebecca Rentea
Concepts (338)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hirschsprung Disease | 16 | 2023 | 53 | 8.060 |
Why?
| | Enterocolitis | 10 | 2023 | 34 | 6.040 |
Why?
| | Laparoscopy | 15 | 2022 | 215 | 4.170 |
Why?
| | Humans | 89 | 2023 | 6599 | 3.830 |
Why?
| | Colorectal Neoplasms | 8 | 2023 | 27 | 3.500 |
Why?
| | Retrospective Studies | 55 | 2023 | 1251 | 3.360 |
Why?
| | Child | 54 | 2023 | 3146 | 3.060 |
Why?
| | Appendicitis | 6 | 2022 | 118 | 3.020 |
Why?
| | Fecal Incontinence | 9 | 2023 | 19 | 2.960 |
Why?
| | Postoperative Complications | 17 | 2023 | 177 | 2.920 |
Why?
| | Alkaline Phosphatase | 7 | 2018 | 18 | 2.760 |
Why?
| | Enterocolitis, Necrotizing | 8 | 2018 | 67 | 2.510 |
Why?
| | Infant | 35 | 2023 | 1396 | 2.420 |
Why?
| | Specialties, Surgical | 3 | 2023 | 13 | 2.250 |
Why?
| | Botulinum Toxins | 4 | 2022 | 7 | 2.060 |
Why?
| | Anal Canal | 14 | 2023 | 23 | 2.040 |
Why?
| | Female | 39 | 2023 | 3436 | 1.940 |
Why?
| | Appendectomy | 5 | 2022 | 103 | 1.930 |
Why?
| | Male | 35 | 2023 | 3197 | 1.880 |
Why?
| | Rectum | 13 | 2023 | 25 | 1.870 |
Why?
| | Infant, Newborn | 19 | 2022 | 790 | 1.860 |
Why?
| | Social Media | 2 | 2023 | 4 | 1.770 |
Why?
| | Child, Preschool | 26 | 2023 | 1459 | 1.680 |
Why?
| | Digestive System Surgical Procedures | 7 | 2021 | 38 | 1.670 |
Why?
| | Ileum | 4 | 2016 | 15 | 1.460 |
Why?
| | Treatment Outcome | 20 | 2023 | 624 | 1.410 |
Why?
| | Cloaca | 5 | 2022 | 5 | 1.370 |
Why?
| | Surgical Procedures, Operative | 2 | 2020 | 12 | 1.340 |
Why?
| | Adolescent | 18 | 2023 | 2087 | 1.320 |
Why?
| | Constipation | 6 | 2022 | 13 | 1.280 |
Why?
| | Quality of Life | 7 | 2023 | 131 | 1.260 |
Why?
| | Enteral Nutrition | 9 | 2023 | 62 | 1.230 |
Why?
| | Pediatrics | 2 | 2020 | 170 | 1.130 |
Why?
| | Perioperative Care | 3 | 2020 | 10 | 1.120 |
Why?
| | Rectal Fistula | 5 | 2023 | 6 | 1.070 |
Why?
| | Animals | 11 | 2022 | 563 | 1.060 |
Why?
| | Enema | 4 | 2022 | 13 | 1.060 |
Why?
| | Patient Discharge | 3 | 2020 | 58 | 1.060 |
Why?
| | Intestinal Mucosa | 2 | 2017 | 34 | 1.040 |
Why?
| | Cytokines | 4 | 2016 | 48 | 1.040 |
Why?
| | Rectal Prolapse | 3 | 2023 | 9 | 1.030 |
Why?
| | Intestines | 5 | 2018 | 26 | 0.970 |
Why?
| | Cecostomy | 2 | 2020 | 2 | 0.930 |
Why?
| | Urethral Diseases | 2 | 2023 | 2 | 0.930 |
Why?
| | Surgical Wound Infection | 4 | 2023 | 43 | 0.920 |
Why?
| | Colitis, Ulcerative | 1 | 2023 | 9 | 0.910 |
Why?
| | Fistula | 2 | 2020 | 2 | 0.890 |
Why?
| | Societies, Medical | 2 | 2022 | 43 | 0.880 |
Why?
| | Physicians | 2 | 2020 | 22 | 0.870 |
Why?
| | Clinical Competence | 3 | 2021 | 32 | 0.850 |
Why?
| | Young Adult | 8 | 2023 | 652 | 0.830 |
Why?
| | Rats | 8 | 2018 | 97 | 0.800 |
Why?
| | Neurotoxins | 1 | 2021 | 3 | 0.790 |
Why?
| | Lung Diseases | 2 | 2018 | 23 | 0.770 |
Why?
| | Colonic Diseases, Functional | 1 | 2020 | 1 | 0.760 |
Why?
| | Operating Rooms | 1 | 2020 | 4 | 0.760 |
Why?
| | Forecasting | 1 | 2020 | 20 | 0.750 |
Why?
| | Inpatients | 1 | 2020 | 44 | 0.740 |
Why?
| | Diagnostic Imaging | 2 | 2017 | 14 | 0.740 |
Why?
| | Fluorescein Angiography | 1 | 2019 | 1 | 0.740 |
Why?
| | Surgical Flaps | 1 | 2019 | 7 | 0.740 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2020 | 62 | 0.730 |
Why?
| | Gastrostomy | 5 | 2022 | 62 | 0.710 |
Why?
| | Rats, Sprague-Dawley | 8 | 2018 | 46 | 0.700 |
Why?
| | Diverticulum | 1 | 2019 | 4 | 0.700 |
Why?
| | Isoenzymes | 1 | 2018 | 19 | 0.660 |
Why?
| | Pelvic Neoplasms | 1 | 2018 | 3 | 0.650 |
Why?
| | Organs at Risk | 1 | 2018 | 3 | 0.650 |
Why?
| | Fertility Preservation | 1 | 2018 | 5 | 0.650 |
Why?
| | Infant, Premature, Diseases | 1 | 2018 | 23 | 0.640 |
Why?
| | Milk | 1 | 2017 | 6 | 0.640 |
Why?
| | HSP70 Heat-Shock Proteins | 1 | 2017 | 4 | 0.640 |
Why?
| | Colostomy | 4 | 2023 | 6 | 0.640 |
Why?
| | Colorectal Surgery | 3 | 2023 | 6 | 0.640 |
Why?
| | Animals, Newborn | 7 | 2018 | 23 | 0.630 |
Why?
| | Counseling | 1 | 2018 | 60 | 0.630 |
Why?
| | Lung | 2 | 2018 | 65 | 0.630 |
Why?
| | Infant Formula | 2 | 2018 | 15 | 0.610 |
Why?
| | Dextrocardia | 1 | 2017 | 3 | 0.610 |
Why?
| | Esophageal Perforation | 1 | 2017 | 4 | 0.600 |
Why?
| | Tracheoesophageal Fistula | 1 | 2017 | 26 | 0.600 |
Why?
| | Esophageal Atresia | 1 | 2017 | 32 | 0.600 |
Why?
| | Interleukin-23 | 1 | 2016 | 2 | 0.590 |
Why?
| | Interleukin-10 | 1 | 2016 | 5 | 0.590 |
Why?
| | Abnormalities, Multiple | 1 | 2017 | 36 | 0.590 |
Why?
| | Milk, Human | 1 | 2016 | 21 | 0.580 |
Why?
| | Radiotherapy | 1 | 2016 | 5 | 0.580 |
Why?
| | Gastrointestinal Microbiome | 1 | 2016 | 8 | 0.580 |
Why?
| | Stress, Psychological | 1 | 2016 | 33 | 0.580 |
Why?
| | Mothers | 1 | 2016 | 37 | 0.570 |
Why?
| | Nitric Oxide Synthase Type II | 2 | 2013 | 3 | 0.570 |
Why?
| | Prospective Studies | 6 | 2023 | 508 | 0.560 |
Why?
| | Adult | 6 | 2023 | 1233 | 0.560 |
Why?
| | Night Care | 1 | 2015 | 2 | 0.540 |
Why?
| | Education, Medical, Graduate | 1 | 2015 | 10 | 0.540 |
Why?
| | Clinical Clerkship | 1 | 2015 | 1 | 0.530 |
Why?
| | Coroners and Medical Examiners | 1 | 2015 | 1 | 0.530 |
Why?
| | Specialty Boards | 1 | 2015 | 1 | 0.530 |
Why?
| | General Surgery | 1 | 2015 | 18 | 0.530 |
Why?
| | Vagina | 4 | 2023 | 5 | 0.520 |
Why?
| | Internship and Residency | 1 | 2015 | 31 | 0.520 |
Why?
| | Surgical Wound Dehiscence | 2 | 2020 | 2 | 0.520 |
Why?
| | Quality Improvement | 1 | 2015 | 60 | 0.510 |
Why?
| | Follow-Up Studies | 7 | 2021 | 315 | 0.510 |
Why?
| | Reoperation | 5 | 2022 | 57 | 0.500 |
Why?
| | Real-Time Polymerase Chain Reaction | 5 | 2016 | 38 | 0.500 |
Why?
| | Pneumothorax | 3 | 2023 | 33 | 0.480 |
Why?
| | Lipopolysaccharides | 4 | 2016 | 20 | 0.470 |
Why?
| | Negative-Pressure Wound Therapy | 1 | 2013 | 1 | 0.470 |
Why?
| | Skin Transplantation | 1 | 2013 | 7 | 0.470 |
Why?
| | Anti-Inflammatory Agents | 1 | 2013 | 11 | 0.450 |
Why?
| | Transcription Factor RelA | 1 | 2012 | 2 | 0.450 |
Why?
| | Wounds and Injuries | 1 | 2013 | 35 | 0.450 |
Why?
| | Stress, Physiological | 1 | 2012 | 6 | 0.450 |
Why?
| | Intestinal Absorption | 1 | 2012 | 2 | 0.440 |
Why?
| | Pyloric Stenosis, Hypertrophic | 2 | 2023 | 23 | 0.430 |
Why?
| | Heart Defects, Congenital | 2 | 2023 | 81 | 0.410 |
Why?
| | Drug Evaluation, Preclinical | 4 | 2016 | 9 | 0.400 |
Why?
| | Hernia, Inguinal | 2 | 2021 | 31 | 0.390 |
Why?
| | Surveys and Questionnaires | 3 | 2022 | 290 | 0.380 |
Why?
| | Biomarkers | 3 | 2018 | 120 | 0.370 |
Why?
| | Urethra | 2 | 2019 | 5 | 0.350 |
Why?
| | Recurrence | 4 | 2023 | 115 | 0.340 |
Why?
| | United States | 3 | 2022 | 646 | 0.280 |
Why?
| | Neural Tube Defects | 2 | 2023 | 2 | 0.280 |
Why?
| | Constriction, Pathologic | 3 | 2023 | 17 | 0.270 |
Why?
| | Tight Junctions | 2 | 2017 | 4 | 0.270 |
Why?
| | Permeability | 2 | 2017 | 7 | 0.270 |
Why?
| | Length of Stay | 6 | 2023 | 227 | 0.260 |
Why?
| | Bladder Exstrophy | 1 | 2023 | 1 | 0.240 |
Why?
| | Educational Status | 1 | 2023 | 20 | 0.240 |
Why?
| | Video Recording | 1 | 2023 | 14 | 0.240 |
Why?
| | Patient-Centered Care | 1 | 2023 | 18 | 0.240 |
Why?
| | Colitis | 1 | 2023 | 12 | 0.230 |
Why?
| | Urinary Fistula | 1 | 2023 | 1 | 0.230 |
Why?
| | Duodenal Obstruction | 1 | 2023 | 15 | 0.230 |
Why?
| | Spinal Dysraphism | 1 | 2023 | 7 | 0.230 |
Why?
| | Intestinal Atresia | 1 | 2023 | 18 | 0.230 |
Why?
| | Colectomy | 1 | 2023 | 13 | 0.230 |
Why?
| | Multicenter Studies as Topic | 1 | 2023 | 17 | 0.230 |
Why?
| | Genitalia, Female | 1 | 2022 | 2 | 0.230 |
Why?
| | Abdominal Injuries | 1 | 2023 | 27 | 0.220 |
Why?
| | Limb Deformities, Congenital | 1 | 2022 | 2 | 0.220 |
Why?
| | Anus, Imperforate | 1 | 2022 | 3 | 0.220 |
Why?
| | Down Syndrome | 1 | 2023 | 39 | 0.220 |
Why?
| | Personal Satisfaction | 1 | 2022 | 9 | 0.220 |
Why?
| | Inflammatory Bowel Diseases | 1 | 2023 | 40 | 0.220 |
Why?
| | Wounds, Nonpenetrating | 1 | 2023 | 60 | 0.220 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2013 | 92 | 0.220 |
Why?
| | Therapeutic Irrigation | 1 | 2022 | 8 | 0.210 |
Why?
| | Testicular Neoplasms | 1 | 2022 | 2 | 0.210 |
Why?
| | Botulinum Toxins, Type A | 1 | 2022 | 4 | 0.210 |
Why?
| | Cicatrix | 1 | 2021 | 5 | 0.210 |
Why?
| | Cryptorchidism | 1 | 2022 | 8 | 0.210 |
Why?
| | Abdominal Cavity | 1 | 2021 | 1 | 0.210 |
Why?
| | Urinary Incontinence | 1 | 2021 | 3 | 0.210 |
Why?
| | Masks | 1 | 2021 | 7 | 0.210 |
Why?
| | Hernia, Umbilical | 1 | 2021 | 15 | 0.210 |
Why?
| | Cholecystectomy, Laparoscopic | 1 | 2021 | 27 | 0.210 |
Why?
| | Information Dissemination | 1 | 2021 | 8 | 0.200 |
Why?
| | Outpatients | 1 | 2021 | 28 | 0.200 |
Why?
| | Child, Hospitalized | 1 | 2021 | 27 | 0.200 |
Why?
| | Clinical Protocols | 2 | 2019 | 35 | 0.200 |
Why?
| | Postoperative Period | 1 | 2021 | 17 | 0.200 |
Why?
| | Social Support | 1 | 2021 | 38 | 0.200 |
Why?
| | Fellowships and Scholarships | 1 | 2021 | 16 | 0.200 |
Why?
| | Fundoplication | 2 | 2018 | 36 | 0.200 |
Why?
| | Risk Factors | 2 | 2023 | 460 | 0.200 |
Why?
| | Surgical Instruments | 1 | 2020 | 4 | 0.190 |
Why?
| | Cost Savings | 1 | 2020 | 10 | 0.190 |
Why?
| | Risk Assessment | 2 | 2018 | 130 | 0.190 |
Why?
| | Acute Disease | 2 | 2017 | 71 | 0.190 |
Why?
| | Appendix | 2 | 2018 | 11 | 0.190 |
Why?
| | Indocyanine Green | 1 | 2019 | 1 | 0.180 |
Why?
| | Probability | 1 | 2020 | 17 | 0.180 |
Why?
| | Replantation | 1 | 2019 | 1 | 0.180 |
Why?
| | Urogenital Abnormalities | 1 | 2019 | 5 | 0.180 |
Why?
| | Bayes Theorem | 1 | 2020 | 30 | 0.180 |
Why?
| | Diagnostic Tests, Routine | 1 | 2020 | 17 | 0.180 |
Why?
| | Cost-Benefit Analysis | 1 | 2020 | 36 | 0.180 |
Why?
| | Telemedicine | 1 | 2021 | 64 | 0.180 |
Why?
| | Exanthema | 1 | 2019 | 4 | 0.180 |
Why?
| | Diarrhea | 1 | 2019 | 18 | 0.180 |
Why?
| | Parents | 1 | 2021 | 149 | 0.180 |
Why?
| | Algorithms | 1 | 2020 | 103 | 0.180 |
Why?
| | Nitric Oxide Synthase | 2 | 2016 | 6 | 0.180 |
Why?
| | Time Factors | 3 | 2018 | 241 | 0.180 |
Why?
| | Cystoscopy | 1 | 2019 | 1 | 0.170 |
Why?
| | RNA, Messenger | 2 | 2016 | 107 | 0.170 |
Why?
| | Clinical Decision-Making | 1 | 2018 | 20 | 0.170 |
Why?
| | Thoracoscopy | 1 | 2018 | 27 | 0.170 |
Why?
| | Robotic Surgical Procedures | 1 | 2018 | 1 | 0.170 |
Why?
| | Urinary Bladder, Neurogenic | 1 | 2018 | 2 | 0.170 |
Why?
| | Neurogenic Bowel | 1 | 2018 | 3 | 0.170 |
Why?
| | Cesarean Section | 1 | 2018 | 3 | 0.170 |
Why?
| | Primary Ovarian Insufficiency | 1 | 2018 | 3 | 0.160 |
Why?
| | Neuromuscular Diseases | 1 | 2018 | 7 | 0.160 |
Why?
| | Puberty | 1 | 2018 | 5 | 0.160 |
Why?
| | Suture Techniques | 1 | 2018 | 10 | 0.160 |
Why?
| | Hepatectomy | 1 | 2018 | 4 | 0.160 |
Why?
| | Attitude of Health Personnel | 2 | 2016 | 49 | 0.160 |
Why?
| | Malnutrition | 1 | 2018 | 8 | 0.160 |
Why?
| | Sutures | 1 | 2018 | 11 | 0.160 |
Why?
| | Embolization, Therapeutic | 1 | 2018 | 12 | 0.160 |
Why?
| | Hepatoblastoma | 1 | 2018 | 7 | 0.160 |
Why?
| | Magnetic Resonance Imaging | 1 | 2019 | 114 | 0.160 |
Why?
| | Evidence-Based Practice | 3 | 2023 | 16 | 0.160 |
Why?
| | Liver Neoplasms | 1 | 2018 | 15 | 0.160 |
Why?
| | Cytoprotection | 1 | 2017 | 1 | 0.160 |
Why?
| | Zonula Occludens-1 Protein | 1 | 2017 | 1 | 0.160 |
Why?
| | Protein Isoforms | 1 | 2017 | 16 | 0.160 |
Why?
| | Gastroesophageal Reflux | 1 | 2018 | 41 | 0.160 |
Why?
| | Missouri | 1 | 2018 | 78 | 0.160 |
Why?
| | Complementary Therapies | 1 | 2017 | 3 | 0.160 |
Why?
| | Ambulatory Surgical Procedures | 1 | 2017 | 14 | 0.150 |
Why?
| | Dopamine | 1 | 2017 | 5 | 0.150 |
Why?
| | Cardiotonic Agents | 1 | 2017 | 5 | 0.150 |
Why?
| | Intraoperative Care | 1 | 2017 | 6 | 0.150 |
Why?
| | Radiography, Thoracic | 1 | 2017 | 12 | 0.150 |
Why?
| | Anticipation, Psychological | 1 | 2016 | 2 | 0.150 |
Why?
| | Postoperative Care | 1 | 2017 | 28 | 0.150 |
Why?
| | Mice | 1 | 2017 | 290 | 0.150 |
Why?
| | Cartilage Diseases | 1 | 2016 | 3 | 0.150 |
Why?
| | Joint Diseases | 1 | 2016 | 4 | 0.150 |
Why?
| | Ribs | 1 | 2016 | 6 | 0.150 |
Why?
| | Costal Cartilage | 1 | 2016 | 4 | 0.150 |
Why?
| | Fluorescent Antibody Technique | 2 | 2014 | 8 | 0.150 |
Why?
| | Radiotherapy Dosage | 1 | 2016 | 2 | 0.150 |
Why?
| | Tumor Necrosis Factor-alpha | 2 | 2014 | 15 | 0.150 |
Why?
| | Down-Regulation | 1 | 2016 | 14 | 0.150 |
Why?
| | Up-Regulation | 1 | 2016 | 25 | 0.140 |
Why?
| | Esophageal Achalasia | 1 | 2016 | 3 | 0.140 |
Why?
| | Funnel Chest | 1 | 2017 | 55 | 0.140 |
Why?
| | Medical Errors | 1 | 2016 | 7 | 0.140 |
Why?
| | Disclosure | 1 | 2016 | 8 | 0.140 |
Why?
| | Databases, Factual | 1 | 2016 | 105 | 0.140 |
Why?
| | Workload | 1 | 2015 | 9 | 0.130 |
Why?
| | Work Schedule Tolerance | 1 | 2015 | 5 | 0.130 |
Why?
| | Personnel Staffing and Scheduling | 1 | 2015 | 14 | 0.130 |
Why?
| | Practice Patterns, Physicians' | 1 | 2016 | 82 | 0.130 |
Why?
| | Operative Time | 3 | 2022 | 31 | 0.130 |
Why?
| | Pregnancy | 2 | 2015 | 203 | 0.130 |
Why?
| | Superoxides | 1 | 2014 | 4 | 0.130 |
Why?
| | Nitric Oxide | 1 | 2014 | 6 | 0.130 |
Why?
| | Hospitals, Pediatric | 1 | 2016 | 178 | 0.130 |
Why?
| | Membrane Glycoproteins | 1 | 2014 | 11 | 0.130 |
Why?
| | Disease Models, Animal | 1 | 2014 | 55 | 0.130 |
Why?
| | Hidradenitis Suppurativa | 1 | 2013 | 1 | 0.120 |
Why?
| | Abdominal Wound Closure Techniques | 1 | 2013 | 1 | 0.120 |
Why?
| | Wound Healing | 1 | 2013 | 7 | 0.120 |
Why?
| | Parenteral Nutrition | 1 | 2013 | 7 | 0.120 |
Why?
| | Osteosarcoma | 1 | 2013 | 19 | 0.120 |
Why?
| | Comorbidity | 1 | 2013 | 61 | 0.120 |
Why?
| | Bone Neoplasms | 1 | 2013 | 23 | 0.110 |
Why?
| | Thoracotomy | 2 | 2023 | 17 | 0.110 |
Why?
| | Chest Tubes | 2 | 2023 | 24 | 0.110 |
Why?
| | Thoracic Surgery, Video-Assisted | 2 | 2023 | 18 | 0.110 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2012 | 21 | 0.110 |
Why?
| | Immunohistochemistry | 1 | 2012 | 36 | 0.110 |
Why?
| | Drug Administration Schedule | 1 | 2013 | 40 | 0.110 |
Why?
| | Systemic Inflammatory Response Syndrome | 1 | 2012 | 16 | 0.110 |
Why?
| | Fluid Therapy | 2 | 2023 | 19 | 0.110 |
Why?
| | Dextrans | 1 | 2012 | 1 | 0.110 |
Why?
| | Hepatitis | 1 | 2012 | 1 | 0.110 |
Why?
| | Fluorescein-5-isothiocyanate | 1 | 2012 | 1 | 0.110 |
Why?
| | Claudins | 1 | 2012 | 1 | 0.110 |
Why?
| | Claudin-1 | 1 | 2012 | 1 | 0.110 |
Why?
| | Claudin-3 | 1 | 2012 | 1 | 0.110 |
Why?
| | Models, Animal | 1 | 2012 | 6 | 0.110 |
Why?
| | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2013 | 60 | 0.110 |
Why?
| | Administration, Oral | 1 | 2012 | 59 | 0.110 |
Why?
| | Incidence | 2 | 2023 | 125 | 0.110 |
Why?
| | Membrane Proteins | 1 | 2012 | 50 | 0.110 |
Why?
| | Pneumonia | 1 | 2012 | 30 | 0.110 |
Why?
| | Gene Expression Regulation | 1 | 2012 | 98 | 0.100 |
Why?
| | Laxatives | 2 | 2022 | 5 | 0.100 |
Why?
| | Herniorrhaphy | 2 | 2021 | 25 | 0.100 |
Why?
| | Urinary Bladder | 2 | 2021 | 5 | 0.090 |
Why?
| | Combined Modality Therapy | 2 | 2019 | 51 | 0.090 |
Why?
| | Biopsy | 2 | 2018 | 56 | 0.080 |
Why?
| | Colon | 1 | 2023 | 12 | 0.060 |
Why?
| | Administration, Intravaginal | 1 | 2023 | 1 | 0.060 |
Why?
| | Mesalamine | 1 | 2023 | 2 | 0.060 |
Why?
| | Anastomotic Leak | 1 | 2023 | 9 | 0.060 |
Why?
| | Anastomosis, Surgical | 1 | 2023 | 22 | 0.060 |
Why?
| | Spinal Cord | 1 | 2023 | 4 | 0.060 |
Why?
| | Rectovaginal Fistula | 1 | 2023 | 2 | 0.060 |
Why?
| | Biological Factors | 1 | 2023 | 1 | 0.060 |
Why?
| | Public Opinion | 1 | 2023 | 2 | 0.060 |
Why?
| | Arizona | 1 | 2023 | 9 | 0.060 |
Why?
| | Arkansas | 1 | 2023 | 9 | 0.060 |
Why?
| | Oklahoma | 1 | 2023 | 11 | 0.060 |
Why?
| | Texas | 1 | 2023 | 16 | 0.060 |
Why?
| | Injury Severity Score | 1 | 2023 | 58 | 0.060 |
Why?
| | Spleen | 1 | 2023 | 29 | 0.060 |
Why?
| | Trauma Centers | 1 | 2023 | 41 | 0.060 |
Why?
| | Spine | 1 | 2022 | 3 | 0.060 |
Why?
| | Trachea | 1 | 2022 | 7 | 0.050 |
Why?
| | Abdomen | 1 | 2022 | 13 | 0.050 |
Why?
| | Atrophy | 1 | 2022 | 6 | 0.050 |
Why?
| | Orchiopexy | 1 | 2022 | 6 | 0.050 |
Why?
| | Testis | 1 | 2022 | 7 | 0.050 |
Why?
| | Liver | 1 | 2023 | 119 | 0.050 |
Why?
| | Electrolytes | 1 | 2021 | 13 | 0.050 |
Why?
| | Carbon Dioxide | 1 | 2021 | 16 | 0.050 |
Why?
| | Hospitals | 1 | 2021 | 38 | 0.050 |
Why?
| | Kidney | 1 | 2022 | 89 | 0.050 |
Why?
| | Referral and Consultation | 1 | 2022 | 33 | 0.050 |
Why?
| | Antibiotic Prophylaxis | 1 | 2021 | 28 | 0.050 |
Why?
| | Perineum | 1 | 2021 | 2 | 0.050 |
Why?
| | Dilatation | 1 | 2021 | 2 | 0.050 |
Why?
| | Patient Satisfaction | 1 | 2021 | 41 | 0.050 |
Why?
| | Cross-Sectional Studies | 1 | 2022 | 317 | 0.050 |
Why?
| | Honduras | 1 | 2020 | 1 | 0.050 |
Why?
| | Hydrocolpos | 1 | 2019 | 1 | 0.050 |
Why?
| | Sacrum | 1 | 2019 | 2 | 0.050 |
Why?
| | Uterus | 1 | 2019 | 8 | 0.050 |
Why?
| | Toilet Training | 1 | 2019 | 1 | 0.050 |
Why?
| | Anti-Bacterial Agents | 1 | 2021 | 238 | 0.040 |
Why?
| | Organ Size | 1 | 2018 | 13 | 0.040 |
Why?
| | Age Factors | 1 | 2019 | 203 | 0.040 |
Why?
| | Jejunum | 1 | 2018 | 3 | 0.040 |
Why?
| | Stomach | 1 | 2018 | 11 | 0.040 |
Why?
| | Intubation, Gastrointestinal | 1 | 2018 | 18 | 0.040 |
Why?
| | Portal Vein | 1 | 2018 | 8 | 0.040 |
Why?
| | Tomography, X-Ray Computed | 1 | 2018 | 116 | 0.040 |
Why?
| | Rupture | 1 | 2016 | 4 | 0.040 |
Why?
| | Syndrome | 1 | 2016 | 33 | 0.040 |
Why?
| | Surgeons | 1 | 2016 | 5 | 0.040 |
Why?
| | Global Health | 1 | 2016 | 12 | 0.040 |
Why?
| | Child Health Services | 1 | 2016 | 24 | 0.040 |
Why?
| | Disease Management | 1 | 2016 | 36 | 0.030 |
Why?
| | Interleukin-6 | 1 | 2015 | 10 | 0.030 |
Why?
| | NG-Nitroarginine Methyl Ester | 1 | 2014 | 4 | 0.030 |
Why?
| | Enzyme Inhibitors | 1 | 2014 | 19 | 0.030 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2014 | 64 | 0.030 |
Why?
| | Polymerase Chain Reaction | 1 | 2015 | 82 | 0.030 |
Why?
| | Middle Aged | 1 | 2016 | 648 | 0.030 |
Why?
|
|
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|